Pathology Holdings Inc, parent company of its flagship laboratory Pathology Inc, Torrance, Calif, a national women’s health laboratory, is entering into a marketing agreement with UK-based Oncimmune®, De Soto, Kan, to market its EarlyCDT®-Lung, the blood test that aids in the risk assessment and the early detection of lung cancer.
Pathology Inc has begun marketinging the test to its network of clients, including independent laboratories, physicians, and hospitals in the California, Illinois, Missouri, and Wisconsin areas.
Lung cancer is the leading cause of cancer death among men and women in the United States, according to the company. Each year more people die of lung cancer than colon, breast, and prostate cancers combined. It is estimated that 226,160 new cases of lung cancer were diagnosed and 160,340 deaths occurred in 2012.
Pathology Inc, a wholly owned subsidiary of Pathology Holdings Inc, is a full-service laboratory offering both clinical and anatomic pathology testing, with nationally recognized pathology expertise in gynecology, genitourinary pathology, gastrointestinal pathology, dermatopathology, hematopathology, and cytopathology.
Patient blood samples are analyzed at Oncimmune’s CLIA-certified laboratory.
[Source: Pathology Inc]
 |
 |
 |
 |
CLP is the only magazine that focuses exclusively on products and technology for the clinical lab industry. Every month, CLP's editorial provides 45,000 pathologists, lab managers, administrators and technologists with comprehensive coverage of new products and technology.
RSS